Bullish indicating open at $55-$60, IPO prices at $37
CareDx, Inc. (NASDAQ:CDNA), a healthcare company currently valued at $670 million and showing strong financial health according to InvestingPro analysis, reported that Secretary and General Counsel Jeffrey Adam Novack sold 2,688 shares of common stock on August 5, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $12.7904, for a total value of $34,380.
The prices for the sales ranged from $12.33 to $13.03, with the stock currently trading near $12.07, down about 46% over the past year. Following the transaction, Novack directly owns 112,930 shares of CareDx. According to InvestingPro’s Fair Value analysis, the stock appears undervalued, with 6 additional ProTips available for subscribers.
The sale was executed under a Rule 10b5-1 trading plan adopted on August 19, 2024. The company maintains a healthy balance sheet with a current ratio of 3.3 and more cash than debt.
In other recent news, CareDx Inc. reported its second-quarter 2025 earnings, which presented a mixed outcome for the company. The earnings per share (EPS) came in at $0.10, exceeding analysts’ expectations of a $0.10 loss. However, the company’s revenue was reported at $86.7 million, which was below the anticipated $90.62 million, resulting in a revenue shortfall of 4.33%. Despite the revenue miss, CareDx’s stock experienced an increase in aftermarket trading. These developments are part of the recent updates concerning CareDx’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.